The increasingly prevalent role of hypomethylating agents (azacitidine, 5-Aza; decitabine, DAC) and growing understanding of mutant IDH1/2 pathophysiology in AML has recently led to exploration of combined therapy with hypomethylators and mutant IDH-targeted therapy. This evidence concerns the gene IDH2 and acute myeloid leukemia.